MycoMed is pleased to announce that the United States Patent and Trademark Office has issued a Notice of Allowance for US Patent Application Pub. No. 20130017561. The allowed claims relate to methods for the detection of Aspergillus fumigatus.
In April 2018, MycoMed Technologies published a paper in Clinical Infectious Disease titled: “Urine Antigen Detection as an Aid to Diagnose Invasive Aspergillosis”. To read, please download the paper below. Urine Antigen Detection as an Aid to Diagnose Invasive Aspergillosis
On March 13, 2018 MycoMed Technologies was awarded US patent# 9,915,657 for a lateral flow device (LFD) for the detection of Aspergillus antigens in urine. Aspergillosis is a common infection in people with weakened immune systems, especially after transplantation or cancer therapy. This simple assay will allow for early detection to prevent severe disease. View [...]
Information sourced from NIH Research Portfolio Online Reporting Tools (RePORT) Easy-to-use, yet sensitive, diagnostic tests for early detection of invasive aspergillosis (IA) are still-unmet medical need, as IA continues causes morbidity and death in patients with compromised immunity. In Phase I, MycoMed Technologies LLC engineered a prototype lateral flow-based device (LFD) called MycoFlow-ASP, and performance [...]
July 2015 Information sourced from TEDCO MII Award Maryland Innovation Initiative (MII) awards by TEDCO are given through the Innovation Commercialization Program, which provides funding to support the commercialization of qualified university technologies at two distinct stages: pre-commercial technology validation and commercialization planning (Phase I & 2 combined), and early-stage product development (company formation) (Phase [...]
Feb 2015 Information sourced from SBIR Source: SBIR Phase I Award The Federal Small Business Innovation Research (SBIR) drives the creation of new businesses and development of wide-ranging technologies; competitive R&D funding available under this program is intended exclusively for small high-tech companies with a goal of commercialization of innovative technologies in diverse fields, from [...]
Information sourced from NIH Research Portfolio Online Reporting Tools (RePORT) Aspergillus polysaccharide antigens are excreted in urine in course of the lung disease, invasive pulmonary aspergillosis. About 200,000 people in the U.S. are at risk for this disease, which kills 40-80% of people who get it. Using a novel monoclonal antibody that detects Aspergillus antigens [...]